Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma)
| Autor: | Yeon Sil Kim, Gi Won Kim, Young Seon Hong, Ihl Bohng Choi, Seok Hyun Son, Suk Woo Yang, Byung Ock Choi |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Conjunctival Neoplasms CHOP Eyelid Neoplasms Cataract Young Adult Lacrimal Duct Obstruction Antineoplastic Combined Chemotherapy Protocols Medicine Humans Radiology Nuclear Medicine and imaging Radiation Injuries Cyclophosphamide Aged Retrospective Studies Salvage Therapy Chemotherapy Radiation business.industry Remission Induction MALT lymphoma Radiotherapy Dosage Lymphoma B-Cell Marginal Zone Middle Aged medicine.disease Marginal zone Surgery Lymphoma Radiation therapy Treatment Outcome Oncology Doxorubicin Vincristine Retreatment Orbital Neoplasms Prednisone Marginal zone B-cell lymphoma Female Radiology business Mucosa-associated lymphoid tissue |
| Zdroj: | International journal of radiation oncology, biology, physics. 77(1) |
| ISSN: | 1879-355X |
| Popis: | Purpose To evaluate the outcomes of patients with localized orbital marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) who were treated with radiotherapy (RT). Methods and Materials We retrospectively reviewed the records of 46 patients who were treated with RT for pathologically confirmed localized stage IE marginal zone B-cell lymphoma of MALT. The radiation dose ranged from 21.6 to 45 Gy (median, 30.6 Gy) at 1.8–2.0 Gy per fraction. Median follow-up duration was 32.3 months (range, 3.1–113.6 months). Results Forty-three patients (93%) achieved complete remission (CR), and three patients (7%) achieved partial remission (PR). Five-year relapse-free survival, cause-specific survival, and overall survival were 93%, 100%, and 100%, respectively. Among the patients with CR, two had recurrence at three sites. One patient relapsed locally and was successfully salvaged with reirradiation. The other patient relapsed in a distant site and was successfully treated with six cycles of CHOP chemotherapy. Late complications were noted in four patients. Two patients developed cataracts at 26 and 37 months after completion of RT. The other two patients developed nasolacrimal duct obstructions at 4 and 11 months after completion of RT. Conclusion Our study showed that a modest dose of RT is an excellent treatment modality with low complication and recurrence rates. We suggest that a dose of 30.6 Gy is tolerable and sufficient for treating orbital MALT lymphoma. Even following recurrence, successful salvage is possible with RT or chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|